Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Cancer & Oncology — Weekly Report — October 26, 2026

Home/Health Insights/Cancer & Oncology — October 26 – November 2, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Cancer & Oncology
Updated Monday · November 16, 2026
Cancer & Oncology · October 26 – November 2, 2026

Cancer & Oncology
Weekly Report

This week's data 195 new clinical trials registered across 10 countries, with 18,951 trials actively recruiting patients worldwide.
Week of October 26 – November 2, 2026
  • 195 new clinical trials registered across 10 countries.
  • 18,951 trials actively recruiting patients worldwide.
  • Notable trial: Longitudinal AI-Assisted Management of Indeterminate Pulmonary Nodules (6000 patients).
  • 6,487 new research papers published.
  • Drug safety: Most reported effect across tracked medications (pembrolizumab, nivolumab, trastuzumab, rituximab, paclitaxel) was Off Label Use.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · October 26 – November 2, 2026
New Trials This Week
195.
registered Oct 26–Nov 2
Recruiting Now
18,951
active trials seeking patients
Countries
10
with active trials this week
Papers Published
6,487
new studies this week
Phase 3 Trials
5
late-stage trials this week
Fig. 01

Trials by country

Count · October 26 – November 2, 2026
China
73
United States
14
Not specified
13
Turkey (Türkiye)
5
Mexico
2
Egypt
2
France
2
Germany
2
Hungary
1
Russia
1
0 19 38 57 73
total
Fig. 02

Trials by phase

Distribution · October 26 – November 2, 2026

New clinical trials registered this week for Cancer & Oncology. Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

195 trials registered for Cancer & Oncology. Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Effect of a Health Belief Model Based Digital Nudge Intervention on Breast Cancer Screening Cancer & Oncology · Ataturk University (NCT07907419) Other Not Yet Recruiting 64 Turkey (Türkiye)
02 Adverse Events During Physical Therapy in Neurocritical ICU Patients Cancer & Oncology · Hospital H+ Queretaro (NCT07901140) Other Active Not Recruiting 47 Mexico
03 Pucotenlimab and Anlotinib in Combination With Chemotherapy Cancer & Oncology · Zhejiang Cancer Hospital (NCT07896668) Phase 2 Recruiting 34 China
04 Brown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography Cancer & Oncology · Istanbul Health and Technology University (NCT07896642) Other Recruiting 60 Turkey (Türkiye)
05 Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN) Cancer & Oncology · Azienda Ospedaliero-Universitaria Careggi (NCT07905313) Phase 2 Not Yet Recruiting 60 N/A
06 A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer Cancer & Oncology · Janssen Research & Development, LLC (NCT07906717) Phase 3 Not Yet Recruiting 400 N/A
07 A Phase I Study of HS-20093 Injection in Combination Therapy in Non-Small Cell Lung Cancer Cancer & Oncology · Hansoh BioMedical R&D Company (NCT07899086) Phase 1 Not Yet Recruiting 102 N/A
08 Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer Cancer & Oncology · Yunnan Cancer Hospital (NCT07907354) Phase 2 Not Yet Recruiting 56 N/A
09 TEAS for Gastrectomy Recovery Cancer & Oncology · The Affiliated Hospital of Qingdao University (NCT07898293) Other Recruiting 104 China
10 Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction Adenocarcinoma Cancer & Oncology · Fujian Cancer Hospital (NCT07902648) Phase 2 Not Yet Recruiting 42 N/A
11 First-in-Human, Multicenter, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of YL-18319 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumors Cancer & Oncology · Shanghai YingLi Pharmaceutical Co. Ltd. (NCT07903207) Phase 1 Not Yet Recruiting 45 N/A
12 An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors Cancer & Oncology · BeOne Medicines (NCT07893535) Phase 1 Not Yet Recruiting 96 N/A
13 FENDRR and CRNDE With DUSP1 and DMBT1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma Cancer & Oncology · Amina Fouad Farag (NCT07906795) Other Completed 62 Egypt
14 Myocardial Injury After Transurethral Resection Cancer & Oncology · Haseki Training and Research Hospital (NCT07900035) Other Completed 89 Turkey (Türkiye)
15 Resistance vs Aerobic Prehabilitation Before Colorectal Cancer Surgery Cancer & Oncology · Semmelweis University (NCT07896174) Other Recruiting 480 Hungary
16 Hydrogel Spacer During Definitive Radiotherapy for Cervical Cancer Cancer & Oncology · Tianjin Medical University Cancer Institute and Hospital (NCT07904182) Other Recruiting 30 China
17 Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer Cancer & Oncology · Marmara University (NCT07907432) Other Not Yet Recruiting 90 Turkey (Türkiye)
18 The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity Cancer & Oncology · Universiti Sains Malaysia (NCT07897409) Phase 2 Not Yet Recruiting 146 Egypt
19 TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients Cancer & Oncology · Tango Therapeutics, Inc. (NCT07897734) Phase 2 Not Yet Recruiting 188 N/A
20 A Phase I Study of Intra-Arterial Yttrium-90 Radioembolization for Unresectable Pancreatic Cancer Cancer & Oncology · National Medical Research Radiological Centre of the Ministry of Health of Russia (NCT07898683) Phase 1 Recruiting 12 Russia
21 Efficacy and Safety of Almonertinib Combined With Recombinant Human Endostatin in the Treatment of Stage IIIB-IV Non-small Cell Lung Cancer Cancer & Oncology · Three Gorges Hospital of Chongqing University (NCT07897019) Other Terminated 1 China
22 Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma Cancer & Oncology · Beijing InnoCare Pharma Tech Co., Ltd. (NCT07896590) Phase 3 Not Yet Recruiting 292 China
23 KLF4 Epigenetic Modulation Cancer & Oncology · Azienda USL Reggio Emilia - IRCCS (NCT07901335) Other Recruiting 170 Italy
24 Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer Cancer & Oncology · Henan Cancer Hospital (NCT07905950) Phase 2 Not Yet Recruiting 155 China
25 A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer Cancer & Oncology · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (NCT07896005) Phase 3 Not Yet Recruiting 436 China
26 A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) Cancer & Oncology · Siren Biotechnology (NCT07902037) Phase 2 Not Yet Recruiting 40 N/A
27 Determinants of Radiation Dermatitis in Head and Neck Cancer Patients Receiving Preventive Photobiomodulation Cancer & Oncology · Hopital Forcilles (NCT07899866) Other Not Yet Recruiting 150 France
28 Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II Study Cancer & Oncology · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (NCT07896681) Phase 2 Recruiting 46 China
29 Organoid Drug Sensitivity-Guided Therapy for Refractory Tumors Cancer & Oncology · Tianjin Medical University Second Hospital (NCT07906301) Other Recruiting 144 China
30 Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer Cancer & Oncology · West China Hospital (NCT07904130) Phase 2 Not Yet Recruiting 32 N/A
31 HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer Cancer & Oncology · Shanghai Hengrui Pharmaceutical Co., Ltd. (NCT07900789) Phase 3 Not Yet Recruiting 825 China
32 GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors Cancer & Oncology · Universität Münster (NCT07897968) Phase 1 Not Yet Recruiting 30 Germany
33 Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia Cancer & Oncology · Medical University of South Carolina (NCT07896213) Phase 1 Not Yet Recruiting 18 United States
34 A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. Cancer & Oncology · Pfizer (NCT07903415) Phase 1 Recruiting 280 United States
35 Implementation of a Pain Management Plan in Major Open Abdominal Surgeries. Cancer & Oncology · National and Kapodistrian University of Athens (NCT07901582) Other Recruiting 58 Greece
36 MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer Cancer & Oncology · Peking University People's Hospital (NCT07894458) Other Recruiting 100 China
37 Longitudinal AI-Assisted Management of Indeterminate Pulmonary Nodules Cancer & Oncology · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (NCT07895277) Other Recruiting 6,000 China
38 Station-Specific Lymph Node Metastasis After Neoadjuvant Chemoimmunotherapy for Middle Thoracic Esophageal Squamous Cell Carcinoma Cancer & Oncology · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (NCT07902544) Other Completed 717 N/A
39 Safety and Efficacy of Belzutifan in Preoperative Preparation for Patients With Pheochromocytoma/Paraganglioma (PPGL) Cancer & Oncology · Longfei Liu,MD (NCT07907341) Phase 4 Recruiting 20 China
40 Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer Cancer & Oncology · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (NCT07907653) Phase 2 Not Yet Recruiting 37 China
41 Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis Cancer & Oncology · Regeneron Pharmaceuticals (NCT07901725) Phase 3 Not Yet Recruiting 382 N/A
42 AI-generated Treatment Recommendations in Precision Oncology Cancer & Oncology · Charite University, Berlin, Germany (NCT07897110) Other Recruiting 191 Germany
43 Phase II Clinical Study of RC148 (ABBV-1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemotherapy) for Unresectable Colorectal Cancer Cancer & Oncology · RemeGen Co., Ltd. (NCT07895355) Phase 2 Not Yet Recruiting 412 China
44 Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia Cancer & Oncology · Rockefeller University (NCT07901959) Phase 1 Recruiting 80 United States
45 A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors Cancer & Oncology · Pfizer (NCT07897721) Phase 1 Not Yet Recruiting 268 N/A
46 Anti-Müllerian Hormone in Breast Cancer Clinical Practice Cancer & Oncology · Masaryk Memorial Cancer Institute (NCT07896772) Other Recruiting 200 Czechia
47 Evaluation of Preoperative Anxiety in Digestive Surgery Cancer & Oncology · University Hospital, Rouen (NCT07897942) Other Recruiting 300 France
48 AXT-1003 Combination With Enzalutamide in Participants With mCRPC Cancer & Oncology · Axter Therapeutics (Beijing) Co., Ltd (NCT07897071) Phase 1 Recruiting 105 China
49 A Study of 68Ga-FAPI Breast PET/MRI Scans in People With Breast Cancer Cancer & Oncology · Memorial Sloan Kettering Cancer Center (NCT07899892) Phase 1 Recruiting 10 United States
50 STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma Cancer & Oncology · National Cancer Institute (NCI) (NCT07902921) Phase 2 Not Yet Recruiting 67 United States
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Cancer & Oncology. These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
pembrolizumab Malignant Neoplasm Progression 1,762
nivolumab Off Label Use 819
trastuzumab Myelosuppression 707
rituximab Off Label Use 5,213
paclitaxel Myelosuppression 1,062

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Cancer & Oncology. If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

6,487 papers

Recently published peer-reviewed studies related to Cancer & Oncology, sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Intraoperative artificial intelligence for brain tumor surgery: from tissue diagnosis to real-time surgical guidance. Goff NK et al. 10.3171/2026.8.FOCUS26439
View abstract

The 2021 WHO CNS tumor classification marked a fundamental shift in neuro-oncology: molecular markers rather than histological appearance now define glioma diagnosis and guide treatment. Yet, in clinical practice the molecular information that matters most to a surgeon-IDH status, 1p/19q codeletion, and methylation class-typically arrives days to weeks after the operation it was meant to inform. Artificial intelligence (AI) is beginning to close that gap. Over the past several years, a growing body of work has demonstrated that AI models can extract diagnostically relevant molecular and histological information from data sources available in the operating room, in real time, at the point of surgical decision-making. In this review, the authors provide a comprehensive overview of state-of-the-art intraoperative AI models available to neurosurgeons during brain tumor resections. They examine AI-augmented approaches to established intraoperative techniques, such as cryosection and fluorescence-guided surgery, before turning to novel technologies including nanopore sequencing and stimulated Raman histology (SRH). The authors conclude by discussing barriers to widespread clinical adoption and what lies ahead for this field. For cryosection, models such as LGNet and the Cryosection Histopathology Assessment and Review Machine (CHARM) have demonstrated strong performance on intraoperative discrimination of primary CNS lymphoma and molecular subtyping of glioma, respectively, with CHARM achieving areas under the receiver operating characteristic curve of 0.88-0.93 across glioma subtypes. In fluorescence-guided surgery, hyperspectral imaging combined with machine learning has enabled classification of tumor type, grade, and IDH mutation based on the 5-aminolevulinic acid (5-ALA) signal with up to 93% accuracy, extracting molecular information from a modality already present in the operating room. For nanopore-based methylation classification, ensemble models such as Rapid Nanopore Brain Intraoperative Classification (ROBIN) have achieved 90% concordance with the final diagnosis prospectively in under 2 hours. In SRH, foundation models for infiltration detection now outperform FLAIR, contrast enhancement, and 5-ALA fluorescence in identifying tumor margins, while molecular classification models have achieved over 90% glioma subtype accuracy in multi-institutional cohorts. At the single-cell level, morphometric profiling of SRH images has revealed nuclear features distinguishing IDH-mutant from IDH-wildtype tumors, opening new avenues for interpretability. Despite this progress, widespread adoption remains limited by the absence of randomized clinical trials demonstrating patient-level benefit. Addressing this gap and realizing the potential of multimodal AI systems that integrate imaging, pathology, and molecular data represent critical next steps for the field.

Neurosurgical focus 2026 Nov 1 PubMed
02 Outcomes of retroperitoneal sarcoma resection: a nine-year retrospective cohort study at a Latin American tertiary center. Restrepo-López J et al. 10.1007/s12094-026-04596-y
View abstract

PURPOSE: To evaluate perioperative complications, overall survival (OS), and relapse-free survival (RFS) in patients undergoing resection for retroperitoneal sarcoma (RPS) at a specialized oncology center in Medellín, Colombia. METHODS: A retrospective cohort study was conducted including 73 patients who underwent curative-intent resection for RPS between 2016 and 2025. Survival probabilities were estimated using the Kaplan-Meier method. Factors associated with OS were evaluated using multivariable Cox proportional hazards regression model. RESULTS: The cohort was predominantly female (63.0%), with a median age of 61 years. Liposarcoma was the predominant histological subtype (74.0%), with dedifferentiated (38.4%) and well-differentiated (35.6%) liposarcomas being the most frequent. Compartmental resection was performed in 50.7% of patients. Major postoperative complications (Clavien-Dindo grade ≥III) occurred in 30.1% of cases. At a median follow-up of 24.9 months, the estimated 5-year OS was 56% (95% confidence interval [CI] 45-71) and 5-year RFS was 50.7% (95% CI 39-65). On multivariable analysis, non-well-differentiated liposarcoma histology (hazard ratio [HR] 7.41; 95%CI 2.12-25.87; p=0.002) and intraoperative blood transfusion (HR 4.56; 95%CI 1.49-13.94; p=0.004) were associated with worse OS. CONCLUSIONS: In this Latin American cohort, non-well-differentiated liposarcoma histology and intraoperative blood transfusion were independent predictors of worse OS following RPS resection. Given the median follow-up of 24.9 months, these survival estimates warrant confirmation in larger multicenter studies.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2026 Nov 1 PubMed
03 FBXO17 promotes osteosarcoma progression by regulating glycolysis and macrophage polarization. Zeng T et al. 10.1007/s10735-026-10983-0
View abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor, characterized by high aggressiveness and poor prognosis. Glycolytic reprogramming and immune microenvironment imbalance contribute to OS progression, but the role of E3 ubiquitin ligases in coordinating glycolysis and macrophage polarization remains unclear. This study aimed to identify key E3 ubiquitin ligases regulating glycolysis and immune microenvironment in OS. Differentially expressed genes (DEGs) were identified from the GSE309091 lncRNA-sequencing dataset using DESeq2. Glycolysis-related genes from GeneCards and E3 ubiquitin ligases from UbiBrowser were integrated with DEGs, and Random Forest machine learning was applied to select core genes. Immune cell infiltration was assessed using CIBERSORT. Key gene expression was analyzed across the GSE309091 and GSE36001 datasets, with protein expression validated via Western blot. OS cell proliferation, cell cycle, apoptosis, invasion, and glycolysis were evaluated using colony formation, EdU, flow cytometry, Transwell assays, and glucose/lactate measurements. THP1-derived macrophages co-cultured with OS cell-conditioned medium were used to assess M1/M2 polarization. The expression of inflammatory cytokines was detected using ELISA. Potential FBXO17 substrates were predicted using UbiBrowser 2.0, and its regulatory relationship with PGC-1α was examined using Co-IP, ubiquitination, CHX-chase. Xenograft mouse models determined in vivo effects of FBXO17. FBXO17, SIAH2, BRCA1, and TRIM32 were identified as core genes associated with glycolysis and ubiquitination. Immune infiltration analysis showed their expression correlated with immune cell composition in OS. FBXO17 was highly expressed in GSE309091 and GSE36001 datasets, as well as in OS cell lines. FBXO17 knockdown inhibited OS cell proliferation, invasion, and glycolytic activity, induced G0/G1 arrest, promoted apoptosis, and enhanced M1 polarization of THP1 macrophages. FBXO17 interacted with PGC-1α and promoted its polyubiquitination and degradation. FBXO17 knockdown slowed PGC-1α degradation, whereas FBXO17 overexpression in FBXO17-knockdown cells reduced PGC-1α protein accumulation and partially restored lactate production. In vivo, FBXO17 silencing significantly suppressed tumor growth. FBXO17 promotes OS progression and glycolytic reprogramming, at least in part, by facilitating the ubiquitination and degradation of PGC-1α and is also involved in regulating macrophage polarization. Therefore, FBXO17 may represent a potential therapeutic target for OS.

Journal of molecular histology 2026 Nov 1 PubMed
04 Pilot study testing varenicline combined with a behavioral intervention for promoting smoking cessation and pain management among patients with cancer. Pollak KI et al. 10.1007/s11764-026-02147-6
View abstract

PURPOSE: Many patients with cancer smoke and also experience pain. Smoking offers short-term pain relief but exacerbates pain long-term. We pilot tested the feasibility, acceptability, and preliminary efficacy of adding varenicline to a combined behavioral treatment that addresses smoking cessation and pain management. METHODS: We conducted a single-arm pilot study in which we provided varenicline paired with a 4-session behavioral treatment that uses the same techniques to help people quit smoking and manage their pain. Our primary outcome was 7-day point prevalence abstinence at 6-months post-randomization. RESULTS: We recruited 19 patients with cancer. 80% of the patients who received the intervention rated it as "helpful" (4 or 5 out of 5) in helping them quit smoking; 60% rated it as helpful in managing their pain. Further, 94% would recommend the program to other patients with cancer. Roughly one-third (35%) (6/17) reported biochemically validated abstinence at 6 months post-randomization. We did not see improvements in reported pain but did see improvements in pain self-efficacy. CONCLUSIONS: Our pilot data suggest the feasibility, acceptability, and preliminary efficacy of this approach for promoting cessation. We need to refine aspects to help address pain, yet addressing pain in addition to smoking cessation might motivate more patients with cancer to join the program. The next step is to conduct a large randomized controlled trial to fully test the efficacy of the combined behavioral program with varenicline. IMPLICATIONS FOR CANCER SURVIVORS: A combined smoking cessation and pain program paired with varenicline might help patients with cancer quit smoking. CLINICAL TRIALS RECORD: NCT06029907.

Journal of cancer survivorship : research and practice 2026 Nov 1 PubMed
05 [Dynamic tongue reconstruction with reinnervated free gracilis muscle flap]. Füzes A et al. 10.1556/650.2026.33652
View abstract

At our center, free flap reconstruction is the gold standard after subtotal or total glossectomy performed for oncological indications. In microvascular reconstructive surgery, several factors must be considered when selecting a flap. In the absence of a flap that meets all requirements perfectly, we strive to restore the functions that most significantly affect the quality of life. Removal of the tongue causes significant impairment of speech, swallowing, and taste sensation. A free flap containing a reinnervated muscle may be suitable for restoring partial tongue movements. Our report presents the use of a reinnervated gracilis musculocutaneous free flap following subtotal glossectomy. During free tissue transplantation, a tissue block removed from another part of the body is transplanted along with its supplying microvessels and nerves using microsurgical techniques. In addition to our standard postoperative management protocol, the flap healed uneventful, and oral feeding was fully restored on the 28th postoperative day. Images and swallowing X-ray taken 8 months postoperatively show the neotongue moving in a cranio-caudal direction. This is the first report of this method in the Hungarian literature. The dynamic movement and volume preservation of the transplanted muscle flap may prevent functional loss, thereby positively affecting the quality of life after treatment. Orv Hetil. 2026; 167(44): 1785-1789.

Orvosi hetilap 2026 Nov 1 PubMed
06 Node-RADS outperforms dual-energy CT-derived quantifications for distinguishing metastatic from non-metastatic regional lymph nodes in resectable gastric cancer. Yao DX et al. 10.1007/s00330-026-12993-8
View abstract

OBJECTIVE: To evaluate and compare the diagnostic performance of Node-RADS, dual-energy CT (DECT)-derived quantitative parameters, and their combination for distinguishing metastatic from non-metastatic regional lymph nodes (LNs) in patients with resectable gastric cancer (GC). MATERIALS AND METHODS: Between Jan 2022 and Oct 2025, 115 consecutive patients with resectable GC who underwent preoperative triple-phase enhanced DECT scans and radical gastrectomy with D2 lymphadenectomy were retrospectively enrolled. A total of 151 regional LNs (70 metastatic, 81 non-metastatic) with region-level pathological confirmation were selected for node-level comparison. Two radiologists independently assessed Node-RADS scores for each LN. LN short diameter (SD) was measured at the venous phase on the maximal axial slice. DECT-derived parameters (CT attenuation at 40 keV, iodine concentration (IC), and effective atomic number (Zeff) across arterial, venous, and delayed phases) were analyzed using a freehand region of interest on the maximal axial slice of the LN. Diagnostic performances were evaluated using receiver operating characteristic curve analysis and compared using the DeLong test. RESULTS: IC at delayed phase (ICDP) was the sole parameter associated with LN involvement. The initial Node-RADS score (cut-off ≥ 3) achieved an AUC of 0.859 (95% CI: 0.793-0.910), significantly outperforming SD (AUC: 0.780, p < 0.05) and ICDP (AUC: 0.612, p < 0.05). Two modified Node-RADS algorithms incorporating ICDP under different rule-in and rule-out criteria were established, but did not improve diagnostic performance beyond the initial Node-RADS scores. CONCLUSION: Node-RADS demonstrates superior diagnostic performance compared with DECT-derived quantitative parameters for identifying metastatic regional LNs in resectable GC, and can be reliably applied in the DECT settings. KEY POINTS: Question Preoperative differentiation of metastatic from non-metastatic regional lymph nodes in resectable gastric cancer remains inaccurate using conventional size criteria. Findings Node-RADS  (AUC = 0.859) outperformed SD diameter (continuous: AUC = 0.780; its > 8 mm dichotomized counterpart: AUC = 0.748) and ICDP (AUC = 0.612) for metastatic LN discrimination. Clinical relevance Node-RADS is a standardized and reproducible criterion that can be applied in dual-energy CT scenarios to effectively identify regional lymph node metastasis in resectable gastric cancer.

European radiology 2026 Nov 1 PubMed
07 The Steroid Symptom Questionnaire Multiple Myeloma (SSQ-MM): translation and cross-cultural adaptation into Danish and Norwegian and initial psychometric evaluation of the Norwegian version. Rosenberg T et al. 10.1007/s11136-026-04415-5
View abstract

PURPOSE: The Steroid Symptom Questionnaire - Multiple Myeloma (SSQ-MM) was developed to assess patient-reported side effects of corticosteroid treatment in multiple myeloma (MM) patients. This study aimed to translate and culturally adapt the SSQ-MM into Danish and Norwegian, and to provide an initial evaluation of the psychometric properties of the Norwegian version. METHODS: Translation and cultural adaptation followed ISPOR good practice guidelines, including forward-backward translation and cognitive debriefing interviews with patients and clinicians. Psychometric evaluation was conducted in newly diagnosed Norwegian MM patients receiving weekly dexamethasone. Internal consistency was assessed using Cronbach's alpha. Construct validity was explored through correlations with EORTC QLQ-C30 constructs and known-groups comparisons based on ECOG performance status. Responsiveness was evaluated across three time points. RESULTS: The Danish and Norwegian translations were considered relevant and acceptable by patients and clinicians. The Norwegian version demonstrated acceptable internal consistency for the total score (α = 0.74) and psychological subscale (α = 0.81). Correlation patterns were generally consistent with predefined hypotheses and known-groups validity was supported by differences in symptom scores according to ECOG performance status. Responsiveness analyses demonstrated significant increases in the total score and several steroid-related symptoms during treatment, whereas fewer changes were observed following treatment discontinuation. Overall, symptom levels were lower than those reported in the original Australian validation study. CONCLUSIONS: Findings from the Norwegian cohort provide preliminary evidence supporting the reliability, construct validity, known-groups validity, and responsiveness of the Norwegian SSQ-MM. Further studies in larger, diverse MM populations are needed to further evaluate its measurement properties.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2026 Nov 1 PubMed
08 [Testicular teratoma with somatic-type malignancy]. Gráczia MC et al. 10.1556/650.2026.33667
View abstract

Most adult testicular tumors are germ cell tumors, among which teratoma may exhibit somatic-type malignant transformation. This phenomenon is uncommon (reported in approximately 3-8% of cases), may show carcinomatous or sarcomatous differentiation and is associated with an unfavorable prognosis and resistance to conventional therapies. We present the case of a 51-year-old man with metastatic testicular cancer. The tumor removed by semicastration was histologically identified as a rhabdomyosarcoma arising in a postpubertal teratoma. Due to the metastatic disease, cytotoxic treatment was initiated with VIP (etoposide-ifosfamide-cisplatin) regimen, followed by an EP (etoposide-cisplatin) protocol because of ifosfamide intolerance. Somatic-type malignant transformation of testicular teratoma is a rare entity that poses significant therapeutic challenges. The presence of a rhabdomyosarcoma component is associated with poor prognosis and often necessitates a sarcoma-oriented oncologic approach. Standard germ cell tumor chemotherapy protocols are generally of limited efficacy; therefore, a multidisciplinary approach, accurate histopathological diagnosis, and appropriate selection of therapy are essential. Orv Hetil. 2026; 167(44): 1790-1795.

Orvosi hetilap 2026 Nov 1 PubMed
09 Is fear of recurrence a determinant of breast self-examination awareness in women who have survived breast cancer? Yılmaz E et al. 10.1007/s00520-026-11436-w
View abstract

BACKGROUND: Fear of cancer recurrence is one of the most prevalent and enduring psychosocial challenges encountered by breast cancer survivors. Although this fear can prompt health-monitoring behaviors such as breast self-examination (BSE), comprehensive survivorship care models addressing these psychological dynamics remain limited. OBJECTIVE: This study was aimed at determining the level of fear of cancer recurrence in women who have survived breast cancer and examining its relationship with their health beliefs and awareness regarding breast self-examination. METHODS: This descriptive, cross-sectional, and correlational study was conducted between June 2024 and October 2024 with 259 breast cancer survivors registered at the radiation oncology outpatient clinic of a tertiary hospital in Türkiye. Data were collected using a Patient Information Form, the Champion Health Belief Model Scale, and the Fear of Cancer Recurrence Inventory. The study was reported in accordance with the STROBE checklist. Data were analyzed using descriptive statistics, independent samples t test, ANOVA, and linear regression analysis. RESULTS: The mean total score for fear of cancer recurrence among the survivors was 1.42 ± 0.82 points. A statistically significant positive correlation was identified between fear of recurrence and health belief model dimensions, particularly perceived severity and health motivation (p < 0.05). Linear regression analysis revealed that fear of cancer recurrence had a significant positive effect on the health belief model (F = 31.690, p < 0.001), explaining 11% of the total variance (R = 0.110). CONCLUSIONS: Fear of cancer recurrence is common among breast cancer survivors and significantly influences their health beliefs and self-monitoring behaviors. While moderate fear may heighten surveillance awareness through BSE, structured psychosocial support and educational programs are essential to help survivors manage recurrence concerns adaptively within holistic nursing care.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2026 Nov 1 PubMed
10 Oleuropein and punicic acid induce oxidative stress and cytotoxicity in MCF-7 breast cancer cells, with protection by peroxiredoxin antioxidant proteins. Diiorio S et al. 10.1007/s11033-026-12952-y
View abstract

BACKGROUND: Breast cancer remains a major cause of cancer-related mortality worldwide, creating a need for novel therapeutic strategies. Natural plant compounds have gained recent attention for their anticancer effects, including oleuropein from olive leaves, and punicic acid from the pomegranate fruit. In the present study, we investigated the effects of oleuropein (OL) and punicic acid (PA) on MCF-7 breast cancer cells and the role of peroxiredoxin (Prdx) antioxidants in mediating these effects. METHODS: MCF-7 cells were treated with different concentrations of OL or PA for 72 h. Viable cell density was measured by MTT assay, cytotoxicity was measured by LDH release, mitochondrial ROS was measured by MitoSOX assay, and lipid peroxidation was measured by MDA assay. The effect of Prdx suppression was determined by transient siRNA transfection, followed by cell treatments and MTT assay. RESULTS: Treatment with OL or PA produced a concentration-dependent reduction in cell viability, increased cytotoxicity, and morphological changes consistent with cellular stress and death, with PA exhibiting greater potency at lower concentrations. Both compounds significantly increased mitochondrial superoxide production, while PA also induced lipid peroxidation. Suppression of Prdx proteins increased cellular susceptibility to OL and PA treatment, with more pronounced effects following PA exposure. CONCLUSIONS: OL and PA induce oxidative stress and cytotoxicity in MCF-7 cells, and peroxiredoxins play a protective role in the cellular response. This study highlights possible efficacy of these agents for treatment, and the importance of antioxidant defense systems in subsequent cancer cell survival.

Molecular biology reports 2026 Nov 1 PubMed
11 Decision regret following rapid genetic testing at the time of breast cancer diagnosis. Hsu LF et al. 10.1002/cncr.70663
View abstract

INTRODUCTION: Genetic testing is increasingly being offered at the time of breast cancer diagnosis to help women guide their treatment decisions. The objective of the current study was to measure decision regret 1 year after genetic testing and to evaluate the factors associated with regret. METHODS: Women from across Canada were referred to receive rapid genetic testing for breast cancer predisposition genes at the time of breast cancer diagnosis (BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53, ATM, and CHEK2). Questionnaires were completed prior to testing and 1-week and 1-year postgenetic testing. Decision regret was measured at one-year. RESULTS: Overall, 871 women participated and the mean age at diagnosis was 46.0 years (range 19-70 years), and 522 (59.9%) of the women were White. Pathogenic variants were found in 83 women (9.5%). The mean score for decision regret was 7.86 (SD 14.17), with 802 women (92.1%) having no regret and 69 participants (7.9%) having regret. Women from racialized groups were more likely to regret their decision compared to White women (13.4% vs 4.4%; p < .001). Those with a BRCA1 or BRCA2 pathogenic variant were significantly more likely to have regret compared to those with a negative result (p = .03). CONCLUSION: A minority of women who have rapid genetic testing at the time of breast cancer diagnosis later regret their decision. Women at greater risk of having decision regret included those who received a positive BRCA1 or BRCA2 genetic test, and those from racialized groups. Follow-up counseling may be warranted for those who experience decision regret.

Cancer 2026 Nov 1 PubMed
12 Liposomal irinotecan and capecitabine plus bevacizumab as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm study. Su D et al. 10.1002/cncr.70671
View abstract

BACKGROUND: Liposomal irinotecan, characterized by its favorable pharmacologic properties and reduced systemic toxicity compared to irinotecan, has demonstrated superior therapeutic potential. This multicenter, single-arm study was conducted to evaluate the efficacy and safety of liposomal irinotecan, capecitabine, and bevacizumab as a second-line treatment for metastatic colorectal cancer (mCRC). METHODS: Patients with histologically confirmed mCRC who had progressed following first-line oxaliplatin-based chemotherapy were enrolled in this study. The treatment regimen was liposomal irinotecan (70 mg/m, d1), capecitabine (1000 mg/m, twice daily, d1-10), and bevacizumab (5 mg/kg, d1). The primary endpoint was progression-free survival. Secondary endpoints included objective response rate, disease control rate, duration of response, overall survival, and safety. RESULTS: Between March 2024 and July 2024, 63 patients were enrolled, with a median age of 60.0 years (range: 37.0-79.0). Among the patients who received at least one tumor assessment, the objective response rate and disease control rate were 22.9% (11/48; 95% CI, 12.0-37.3) and 89.6% (43/48; 95% CI, 77.3-96.5), respectively. With a median follow-up of 16.2 months (range: 0.5-28.5), the median progression-free survival was 8.1 months (95% CI, 7.3-8.9), and the median overall survival was 19.5 months (95% CI, 15.2-23.8). The most common grade 3 to 4 adverse events were diarrhea (12.7%), neutropenia (11.1%), and fatigue (6.3%). CONCLUSIONS: The combination of liposomal irinotecan, capecitabine, and bevacizumab demonstrated promising antitumor activity and a manageable safety profile in patients with mCRC who had failed first-line oxaliplatin-based therapy. These results suggested that this regimen is a clinically feasible second-line treatment option for mCRC.

Cancer 2026 Nov 1 PubMed
13 Conversion Surgery After HAIC-Based Combination Therapy with Targeted Therapy and Immune Checkpoint Inhibitors for Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study. Zhang X et al. 10.2147/JHC.S644129
View abstract

BACKGROUND: For selected patients whose initially unresectable hepatocellular carcinoma (HCC) responds to hepatic arterial infusion chemotherapy (HAIC)-based combination treatment, conversion surgery may provide an opportunity for curative-intent management. We quantified the frequency of conversion surgery, examined factors associated with surgical conversion, and assessed survival and pathological outcomes using analyses that accounted for immortal time bias. METHODS: We conducted a single-center retrospective cohort study of 216 patients with initially unresectable HCC who received HAIC together with targeted therapy and immune checkpoint blockade from September 2020 through June 2023. The relationship between conversion surgery and survival was examined with time-dependent Cox regression and a prespecified 180-day landmark analysis. Two hepatopathologists independently assessed the pathological response. RESULTS: 47 (21.8%) patients underwent conversion surgery, and 16 (34.0%) achieved pathological complete response (pCR). Median overall survival (OS) was 22.7 months (95% confidence interval [CI], 21.1-25.8), and median progression-free survival (PFS) was 13.7 months (95% CI, 10.9-16.2). In adjusted 180-day landmark analyses including 211 patients for OS and 166 patients for PFS, conversion surgery was associated with lower hazards of death (hazard ratio [HR], 0.30; 95% CI, 0.16-0.59; < 0.001) and progression or death (HR, 0.32; 95% CI, 0.16-0.64; = 0.001); time-dependent Cox models produced consistent findings. Albumin ≥ 35 g/L was associated with higher odds of conversion surgery (odds ratio [OR], 5.47; 95% CI, 1.75-17.06), whereas multifocal tumors were associated with lower odds (OR, 0.13; 95% CI, 0.06-0.29). Among resected patients, pCR was associated with favorable postoperative outcomes in exploratory unadjusted analyses. CONCLUSION: 47 of 216 patients (21.8%) underwent conversion surgery after HAIC-based combination therapy. Conversion surgery was associated with favorable OS and PFS after accounting for treatment timing. However, causal inference remains limited by residual confounding and treatment-selection bias in this retrospective study. The prognostic value of pCR requires validation in larger prospective cohorts.

Journal of hepatocellular carcinoma 2026 PubMed
14 Early Assessment of Circulating Tumor Cells and Their PD-L1 Expression as Predictive Biomarkers in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy: An Exploratory Study. Grolleau E et al. 10.2147/ITT.S614110
View abstract

INTRODUCTION: The prognosis of metastatic non-small cell lung cancer (mNSCLC) has improved in recent years but therapeutic benefit remains heterogeneous, underscoring the need for reliable biomarkers. Liquid biopsy techniques, including the analysis of circulating tumor cells (CTCs) and Programmed death-ligand 1 (PD-L1) expression on CTCs (PD-L1-CTCs), have emerged as promising tools. MATERIALS AND METHODS: We conducted a retrospective study in a cohort of mNSCLC patients treated with Immune Checkpoint Inhibitors (ICIs) to evaluate the predictive value of these biomarkers at baseline and at an early time point during treatment. CTCs were captured with the ClearCell FX platform and then assessed for PD-L1 by immunostaining. Therapeutic drug monitoring of nivolumab and pembrolizumab was performed. RESULTS: Thirty-seven mNSCLC patients were enrolled. The median CTCs count was 35 CTCs per 7.5 mL of whole blood (standard deviation ± 939). PD-L1-CTCs were detected in 51% of patients. No correlation was found between PD-L1-CTCs and PD-L1 on tumor Formalin-Fixed, Paraffin-Embedded (FFPE) tissue. Higher-than-median CTCs count was associated with a trend toward worse outcomes. In contrast, PD-L1 expression on CTCs did not predict treatment response. Most patients presented a trough concentration of ICI at cure 3 above 10 µg/mL, regardless clinical response. CONCLUSION: Baseline CTCs levels tended to be associated with clinical outcomes, whereas PD-L1 expression on CTCs was not. Early evaluation of changes in these two parameters did not improve outcome prediction under ICI treatment. Larger studies with longer follow-up and more in-depth analyses are warranted to further define the prognostic and predictive value of CTC-based biomarkers.

ImmunoTargets and therapy 2026 PubMed
15 Reconsidering blood refusal: Implications of updated Jehovah's Witness acceptance of autologous transfusion. Glover RT et al. 10.46989/001c.172919
View abstract

Refusal of blood transfusion has historically been associated with members of the Jehovah's Witness (JW) faith. As such, a range of transfusion-sparing strategies have been developed for these individuals and others who refuse standard blood transfusion. Techniques that maintain blood in continuous circuit with the patient are often acceptable and have been used in operative settings, including cell salvage and acute normovolemic hemodilution. By contrast, blood that has been collected and stored for later use has traditionally been considered unacceptable, which has limited the use of both allogeneic and autologous blood products. A March 2026 update by the governing body of Jehovah's Witnesses, The Watch Tower Bible and Tract Society of Pennsylvania, moves decisions about the storage and reinfusion of a patient's own blood into the realm of individual conscience, which may expand the use of autologous transfusion. Given this change, requests for autologous transfusion from JW patients may increase. In this letter, we offer practical guidance on balancing respect for patient autonomy and religious belief with the medical and logistical challenges of autologous blood transfusion.

Clinical hematology international 2026 PubMed
16 Sudanese Pharmacists' Knowledge, Attitudes, Practices, and Barriers Regarding Breast Cancer Endocrine Therapy: A Cross- Sectional Survey. Hassan TM et al. 10.2147/BCTT.S641349
View abstract

BACKGROUND: Breast cancer represents one of the most frequent causes of morbidity and mortality in Sudan, and late diagnosis, lack of access to specialist care, and socioeconomic factors limit the results of its treatment. Endocrine therapy, which includes the use of tamoxifen, letrozole, and anastrozole, is of vital importance for treating hormone-receptor-positive breast cancer. However, their proper use depends on pharmacists' activities, which should include counselling, ensuring adherence, monitoring adverse effects and interactions, and identifying treatment problems. METHODS: In the current cross-sectional study, the knowledge, attitude, practice, and barriers of Sudanese pharmacists toward breast cancer pharmacotherapy were studied using a questionnaire survey method. The structured, self-administered online questionnaire was distributed across Sudan. Descriptive and inferential statistical methods were used, including the binary logistic regression, which helped to reveal the independent predictors of good knowledge, favorable attitudes, and practice. The significance level was established to be p < 0.05. RESULTS: A total of 405 Sudanese pharmacists filled out the questionnaire. Most respondents were females (65.9%), aged from 26 to 30 years old (44.0%), had a bachelor's degree in pharmacy (70.9%), and worked in community pharmacies (75.3%). Overall, 52.6% showed good knowledge, 50.1% had a positive attitude, and 50.1% reported good practice concerning tamoxifen, letrozole, and anastrozole. Knowledge was significantly associated with job type (p = 0.002), and practice depended on job type (p = 0.001) and participation in educational programs and workshops (p < 0.001). Also, knowledge was significantly associated with practice (p < 0.001). Multivariable analysis revealed that pharmacists with more than 10 years of work experience had higher odds of good knowledge than those with less than 5 years of experience (OR = 3.095, 95% CI: 1.188-8.064; p = 0.021), while clinical pharmacists had higher odds of good knowledge than those who did not report clinical pharmacy work (OR = 2.827, 95% CI: 1.006-7.942; p = 0.049). No examined factors were significantly associated with positive attitude. Attendance at an educational program was associated with higher odds of good practice (OR = 3.546, 95% CI: 2.240-5.612; p < 0.001). CONCLUSION: Moderate knowledge and practice in combination with a favorable attitude toward breast cancer endocrine therapy were revealed among Sudanese pharmacists. Job type and education in oncology represent the main predictors of pharmacists' practice, highlighting the need for structured continuing education and stronger pharmacist integration into multidisciplinary cancer care.

Breast cancer (Dove Medical Press) 2026 PubMed
17 Biomaterial-Enabled Delivery Strategies to Overcome Treatment Resistance in Medulloblastoma. Sheng Z et al. 10.2147/IJN.S640704
View abstract

Multimodal therapy has improved survival in medulloblastoma (MB), yet recurrence, neuraxis dissemination, and treatment-related late effects remain major challenges. Treatment resistance reflects clonal evolution, drug efflux, altered DNA-damage and apoptotic responses, treatment-persistent cells, the tumor microenvironment, and inadequate active-drug exposure across the blood-brain barrier (BBB), postoperative residual compartments, and cerebrospinal fluid (CSF) spaces. Biomaterials can modify intracranial distribution, local retention, combination exposure, and intracellular cargo release. This review evaluates direct MB evidence for polymeric and lipid nanomedicines, biomimetic and virus-derived platforms, magnetic materials, extracellular vesicles, and hydrogels across intracranial solid lesions, postoperative residual disease, and neuraxis dissemination, while defining the limits of extrapolation from related tumors. Systemic nanomedicines currently provide the broadest evidence chain from formulation optimization to brain or tumor exposure, target modulation, and antitumor activity. Disease-matched studies also support active transendothelial transport and intrathecal nanoparticle therapy for metastatic MB. Most evidence remains preclinical; direct evidence of reversal of established treatment resistance is limited, and human studies largely assess route feasibility and safety. Progress will require quantitative active-cargo pharmacokinetics and pharmacodynamics, disease- and route-matched models, juvenile neurodevelopmental safety testing, and defined product quality attributes to determine whether these platforms can widen the therapeutic window or restore treatment sensitivity.

International journal of nanomedicine 2026 PubMed
18 Circulating Biomarkers with Artificial Intelligence for Clinical Risk Assessment and Therapeutic Monitoring: Evidence, Limitations, and Translation. Wei W et al. 10.2147/TCRM.S612081
View abstract

Circulating biomarkers, particularly cell-free DNA (cfDNA), are transforming contemporary medicine through their capacity to provide dynamic, minimally invasive assessments of disease dynamics. Their clinical utility has broadened substantially to include oncology, cardiovascular conditions, transplant monitoring, infectious diseases, and persistent inflammatory disorders. Nevertheless, the increasing complexity and volume of biomarker-related data pose substantial challenges, necessitating the integration of artificial intelligence (AI) and machine learning methodologies for improved data interpretation, risk assessment, and clinical decision-making. This review presents a thorough examination of recent progress in the integration of circulating biomarkers with AI within therapeutic contexts and clinical risk management. It outlines the translational trajectory from molecular signatures to precision medicine, addresses present constraints, and explores prospective developments. The objective of this review is to serve as a systematic resource for both clinical practice and research, thereby promoting the evolution of personalized medicine through innovative, biomarker-driven strategies supported by AI.

Therapeutics and clinical risk management 2026 PubMed
19 Local Recurrence and Oncological Outcomes After Transanal Total Mesorectal Excision With Intersphincteric Resection for Lower Rectal Cancer: A Nationwide Multicenter Cohort Study (Ta-Ta-Mi Study). Tanabe K et al. 10.1002/ags3.70304
View abstract

AIM: Transanal total mesorectal excision (TaTME) combined with intersphincteric resection (ISR) has emerged as a sphincter-preserving surgical option for very low rectal cancer. However, multicenter data evaluating oncological outcomes and risk factors for local recurrence (LR) following TaTME with ISR remain limited. This study aimed to evaluate oncological outcomes and identify risk factors for LR in patients undergoing TaTME with ISR. METHODS: This multicenter retrospective cohort study included patients who underwent TaTME with ISR for lower rectal cancer at 26 institutions participating in the Japan Society for Laparoscopic Colorectal Surgery. Oncological outcomes and clinicopathological factors associated with LR were analyzed. Multivariable analysis was performed to identify independent risk factors for LR. RESULTS: A total of 224 patients were included. The 3-year LR, recurrence-free survival (RFS), and overall survival (OS) rates were 7.3%, 79.5%, and 98.1%, respectively. Multivariable analysis identified circumferential resection margin (CRM)/radial margin (RM) positivity as the key independent risk factor for LR. In contrast, pathological features, including histopathological classification, lymphatic invasion, vascular invasion, perineural invasion, and tumor budding, reflected tumor biological aggressiveness rather than surgical performance. A biological aggressiveness score demonstrated a stepwise increase in LR risk according to the number of adverse pathological factors. CONCLUSION: TaTME combined with ISR is a feasible sphincter-preserving option for lower rectal cancer, with acceptable oncological outcomes in a nationwide multicenter cohort. Both surgical factors, particularly margin status, and tumor biological characteristics may contribute to LR risk. Careful margin assessment and close postoperative surveillance are essential for optimizing oncological outcomes.

Annals of gastroenterological surgery 2026 Oct 31 PubMed
20 Protein Lactylation in Cancer: From Mechanisms to Therapy. Huang W et al. 10.1002/mco2.71106
View abstract

Protein lactylation has emerged as a metabolically responsive posttranslational modification linking lactate accumulation to epigenetic and functional adaptation in cancer. Initially identified on histones, lactylation is now recognized on diverse nonhistone proteins involved in DNA damage repair, immune regulation, redox homeostasis, metabolic remodeling, and cellular plasticity. However, current evidence remains fragmented across treatment modalities, and many reported lactylation events lack site-specific functional validation and translational assessment. This review addresses this gap by integrating the metabolic and enzymatic basis of protein lactylation with its roles in chemotherapy, radiotherapy, targeted therapy, and immunotherapy. We critically examine how lactylation may promote tumor persistence under therapeutic pressure by enhancing genome maintenance, immune evasion, stress-survival signaling, metabolic adaptability, and tumor microenvironment remodeling. We also evaluate emerging strategies targeting lactate production and transport, lactylation-regulating enzymes, and functionally validated substrates, including their potential use in combination therapies. Finally, we discuss major barriers to clinical translation, including incomplete characterization of regulatory enzymes, limitations in site-specific lactylome mapping, insufficient causal validation, lack of clinically qualified biomarkers, tumor metabolic heterogeneity, and challenges in achieving therapeutic selectivity. Collectively, protein lactylation represents an emerging mechanistic framework for understanding cancer treatment adaptation and a potentially targetable axis whose clinical relevance requires rigorous validation.

MedComm 2026 Nov PubMed
21 From fistula to malignancy: rectal mucinous adenocarcinoma arising in a chronic perianal fistula, a rare diagnostic challenge. AlMuhsin AM et al. 10.1093/jscr/rjag1003
View abstract

Perianal fistula is a common surgical complaint that general surgeon frequently face in daily clinical practice. However, an adenocarcinoma arising from a fistula is an uncommon entity that has the propensity to mimic benign conditions leading to a delays in diagnosis and management. We present a case of a 42-year-old patient with long standing history of perianal fistula. Given the prolonged nature of his disease further investigations were warranted. While colonoscopy ruled out luminal disease, pelvic magnetic resonance imaging and deep tissue biopsies confirmed the diagnosis of invasive adenocarcinoma with focal mucinous component. The patient required neoadjuvant treatment followed by extra levator abdominoperineal excision and pelvic floor reconstruction. At 5-year follow up, the patient didn't have local recurrence or distant metastasis.

Journal of surgical case reports 2026 Oct PubMed
22 Supportive Care in Patients with End-Stage Lung Cancer: Comparing Aromatherapy, Massage, Their Combination, and Usual Care. Deng S et al. 10.2147/JPR.S648470
View abstract

BACKGROUND: Patients with end-stage lung cancer often experience pain, anxiety and stress, but evidence comparing supportive care approaches near the end of life is limited. METHODS: We retrospectively analysed routine clinical records from 130 patients with end-stage lung cancer. A total of 299 care encounters were classified as aromatherapy, massage, combined aromatherapy and massage, or usual care. Pain, anxiety and stress were scored from 0 to 10 before and after care at three periods before death: 8-12 weeks, 2-4 weeks and the final 7 days. RESULTS: Combined aromatherapy and massage was associated with the greatest improvements in pain, anxiety, and stress at all three time points. At 8-12 weeks before death, mean improvements with combined care were 1.65 points for pain, 1.55 for anxiety and 1.73 for stress. Massage showed greater pain improvement than aromatherapy, whereas aromatherapy showed similar or slightly greater anxiety improvement. Symptom improvement decreased as death approached. More than 90% of care sessions were completed, with 12 minor adverse events and no serious adverse events reported. CONCLUSION: Aromatherapy, massage and especially their combination were associated with immediate symptom improvement. Prospective studies are needed to confirm these findings.

Journal of pain research 2026 PubMed
23 Quantitative Oculomotor Abnormalities in Episodic and Chronic Migraine: A Cross-Sectional Comparative Study. Li Y et al. 10.2147/JPR.S635130
View abstract

BACKGROUND: Migraine is a primary headache disorder accompanied by potential oculomotor dysfunction, yet the differences in eye movement performance between episodic migraine (EM) and chronic migraine (CM) remain insufficiently clarified. This study aimed to compare clinical headache-related indicators and quantitative oculomotor task parameters among healthy controls, total migraine patients, EM and CM subgroups, and explore characteristic oculomotor differences between EM and CM. METHODS: This study adopted a cross-sectional design. A total of 242 patients with migraine and 47 healthy controls were included. Of the patients with migraine, 199 were classified as having episodic migraine and 41 as having chronic migraine; two could not be classified because of missing headache-frequency data. Demographic and clinical data including sex, age, Headache Impact Test-6 (HIT-6) and Migraine Disability Assessment (MIDAS) scores were collected. All participants completed a battery of quantitative oculomotor paradigms, including prosaccade, gap saccade, overlap saccade, antisaccade, memory-guided saccade and smooth pursuit tasks. Group differences were primarily evaluated using independent-samples tests, with Welch's correction applied when variances were unequal. Effect sizes and 95% confidence intervals were reported, and Mann-Whitney -tests were performed as sensitivity analyses.; P < 0.05 was defined as statistically significant. Given the exploratory nature of the analyses, no adjustment for multiple comparisons was applied. RESULTS: Sex and age showed no intergroup differences (P>0.05). CM had higher HIT-6 and MIDAS scores than EM (<0.05). Compared with controls, patients with migraine had lower antisaccade peak velocity (mean difference, -129.95 °/s; 95% CI, -210.74 to -49.17; Cohen's d=0.50), whereas the difference in antisaccade error rate was not robust in the sensitivity analysis. Compared with EM, CM showed abnormalities in saccade latency, completion time, velocity, memory-guided saccade accuracy, and inhibition failures, with absolute Cohen's d values ranging from 0.35 to 0.58. CONCLUSION: Migraine patients manifest impaired inhibitory control during antisaccade execution compared with healthy individuals. Distinct quantitative oculomotor abnormalities including prolonged saccade latency, reduced saccadic velocity, decreased memory-guided saccade accuracy and elevated inhibitory failure frequency are prominent in CM rather than EM. Quantitative oculomotor assessments measures may represent candidate correlates of migraine subtype, but these exploratory findings require validation in larger, independent cohorts.

Journal of pain research 2026 PubMed
24 Anastrozole-Induced Liver Injury: A Pooled Analysis of 11 Published Case Reports. Tang WR et al. 10.2147/BCTT.S634358
View abstract

Anastrozole, a first-line adjuvant treatment for estrogen receptor-positive breast cancer, is generally well-tolerated but has been rarely associated with idiosyncratic liver injury. This brief report pooled and retrospectively analyzed 11 published case reports from PubMed and Web of Science. All identified patients were female, with a mean age of 70, suggesting that most reported cases were elderly white women. The latency period from drug initiation to injury was highly variable, ranging from days to years. Laboratory findings primarily indicated a hepatocellular pattern of injury, and most patients had no significant imaging abnormalities. Critically, discontinuation of anastrozole was the cornerstone of management, leading to recovery in 90% of cases, although one fatal outcome was reported. This analysis underscores that while rare, anastrozole-induced liver injury can be severe. Clinicians should be aware of this potential toxicity, monitor liver function appropriately, and discontinue the drug promptly if injury is suspected. Unfortunately, these findings are limited by the small sample size and publication bias inherent to case-report-based analyses. Further research is needed to understand the underlying mechanisms and risk factors.

Breast cancer (Dove Medical Press) 2026 PubMed
25 Association between antibiotic exposure and survival outcomes in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Chen S et al. 10.7717/peerj.21840
View abstract

OBJECTIVE: Patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs) are frequently exposed to antibiotics. This study aims to evaluate the impact of antibiotic use on the survival outcomes of HCC patients treated with ICIs. METHODS: This study followed the PRISMA guidelines and systematically retrieved literature from PubMed, Embase, and Cochrane Library databases up to August 7, 2026. Studies comparing the clinical outcomes (overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR)) of HCC patients receiving ICI treatment with and without antibiotic exposure were included. The quality of the studies was assessed using the Newcastle-Ottawa Scale. Before conducting the meta-analysis, the original hazard ratios (HRs)/odd ratios (ORs) and their 95% CIs were log-transformed to achieve a normal distribution. Statistical analysis was performed using Stata 15 software, and pooled HRs/ORs with 95% CIs were calculated. RESULTS: A total of 12 retrospective cohort studies were included, involving 3,643 patients (761 exposed to antibiotics). The results showed that the median OS of the antibiotic-exposed group (12.2 months) was shorter than that of the non-exposed group (17.0 months). The meta-analysis indicated that antibiotic use was significantly associated with poorer OS (HR = 1.29, 95% CI [1.17-1.41]). Sensitivity analyses confirmed the robustness of the OS finding. In terms of PFS, the median PFS of the antibiotic-exposed group (5.2 months) was shorter than that of the non-exposed group (7.5 months), and antibiotic use was also significantly associated with poorer PFS (HR = 1.27, 95% CI [1.01-1.59]), although this association was not robust in sensitivity analyses. The analyses of ORR and DCR did not show significant differences between the groups. No significant publication bias was detected on the basis of visual inspection of funnel plots and Egger's and Begg's tests. CONCLUSION: For HCC patients receiving ICI therapy, antibiotic exposure was significantly associated with reduced OS. A significant association with poorer PFS was also observed, although this finding was not robust in sensitivity analyses and should therefore be interpreted with caution. No statistically significant differences were observed for ORR or DCR.

PeerJ 2026 PubMed
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Cancer & Oncology
  • Week: October 26 – November 2, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 6:04 AM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —